Dewpoint Therapeutics Raises $77M Series B Financing to Advance the Development of Drugs That Target Biomolecular Condensates
Dewpoint Therapeutics Raises $77M Series B Financing to Advance the Development of Drugs That Target Biomolecular Condensates
09/29/20, 10:18 AM
Location
boston
Money raised
$77 million
Round Type
series b
Dewpoint Therapeutics, the biomolecular condensates company, today announced it has raised $77 million in a Series B financing. The round was led by ARCH Venture Partners, with participation from new investors Maverick Ventures and Bellco Capital, and existing investors Leaps by Bayer, EcoR1 Capital, Polaris Partners, Samsara BioCapital, and Innovation Endeavors.
Company Info
Location
boston, massachusetts, united states
Additional Info
Biomolecular condensates, formed through a process called phase separation, are membraneless droplets inside cells that facilitate molecular interactions and help cells perform vital functions. Condensates have been shown to play a critical role in key biological processes and in serious, intractable diseases across areas including neurodegeneration, cancer, inflammation, infectious disease, metabolic disease, and rare genetic disorders. The first condensates were observed more than 100 years ago. It is only in the last dozen years, though, that scientists—including Dewpoint founders Tony Hyman of the Max Planck Institute in Dresden and Rick Young of the Whitehead Institute—have begun to understand the dynamic nature and function of condensates. Dewpoint develops drugs that exploit this biology. Prior to the discovery of biomolecular condensate function, it was unknown how the right molecules could find each other at the right time to catalyze important processes in the crowded molecular environment of the cell.